Chronic myeloid leukaemia

  title={Chronic myeloid leukaemia},
  author={R{\"u}diger Hehlmann and Andreas Hochhaus and Michele Baccarani},
  journal={The Lancet},
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Recommendations for monitoring patients on the basis of their mutational status are given, including recommendations for BCR-ABL mutational analysis along with other tyrosine kinase inhibitors (TKIs) that should be administered according to the mutations harbored in a patient.
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
An overview on CML clinical management and a summary on the main targeted drugs available in that context are provided.
[Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].
CML is exceptional amongst neoplasias since its underlying pathomechanism has been elucidated, and potent well tolerated targeted drugs, the tyrosine kinase inhibitors (TKI), are available for treatment.
Nilotinib for the treatment of chronic myeloid leukemia
An overview of clinical results in imatinib-resistant or -intolerant patients that led to its current approval as second-line therapy for the chronic and accelerated phases of CML and the role of nilotinib as first- line therapy, in combination strategies and in the context of specific BCR-ABL mutations are given.
What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?
The long-term follow-up data from the original IRIS study reported that the estimated 10year freedom from progression (to accelerated phase or blast crisis) rate was 92%, which was higher than the expected 10year overall survival rate of 83%, demonstrating that in fact, CP-CML patients are dying from diseases other than CML.
Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
The chance for TFR has become feasible for approximately 40-60 % C ML patients in deep and durable molecular remission and represents a further important milestone in the management of CML patients.
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Imatinib is the first-line treatment for CML, however, imatinib does not appear to be capable to eliminate all leukemia cells in the patients and pre-existing as well as acquired resistance to the drug has been increasingly recognized.
Current role of stem cell transplantation in chronic myeloid leukaemia.
Chronic myeloid leukemia
The introduction of imatinib and other TKIs has dramatically improved the clinical outcome for CML patients, and today, the vast majority of patients receiving TKI treatment in chronic phase (CP) remain in complete hematologic and cytogenetic remission with low to undetectable BCR-ABL1 fusion transcripts.